Outcomes of long-term nivolumab and subsequent chemotherapy in Japanese patients with head and neck cancer: 2-year follow-up from a multicenter real-world study

Yasumatsu, Ryuji; Shimizu, Yasushi; Hanai, Nobuhiro et al.

International journal of clinical oncology, 2021, 27, 95-104

Permalink : https://hdl.handle.net/2115/83677

このアイテムのアクセス数:473件（2026-05-12 14:23 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
https://doi.org/10.1007/s10147-021-02047-y     20

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/83677
タイトル
Outcomes of long-term nivolumab and subsequent chemotherapy in Japanese patients with head and neck cancer: 2-year follow-up from a multicenter real-world study
著者
Yasumatsu, Ryuji ; Shimizu, Yasushi ; Hanai, Nobuhiro ; Kariya, Shin ; Yokota, Tomoya ; Fujii, Takashi ; Tsukahara, Kiyoaki ; Ando, Mizuo ; Hanyu, Kenji ; Ueda, Tsutomu ; Hirakawa, Hitoshi ; Takahashi, Shunji ; Ono, Takeharu ; Sano, Daisuke ; Yamauchi, Moriyasu ; Watanabe, Akihito ; Omori, Koichi ; Yamazaki, Tomoko ; Monden, Nobuya ; Kudo, Naomi ; Arai, Makoto ; Yonekura, Syuji ; Asakage, Takahiro ; Nekado, Takahiro ; Yamada, Takayuki ; Homma, Akihiro
著者名
Yasumatsu, Ryuji
e-Rad_Researcher
10374513
著者名
Shimizu, Yasushi
著者名
Hanai, Nobuhiro
著者名
Kariya, Shin
著者名
Yokota, Tomoya
著者名
Fujii, Takashi
著者名
Tsukahara, Kiyoaki
著者名
Ando, Mizuo
著者名
Hanyu, Kenji
著者名
Ueda, Tsutomu
著者名
Hirakawa, Hitoshi
著者名
Takahashi, Shunji
著者名
Ono, Takeharu
e-Rad_Researcher
80550368
著者名
Sano, Daisuke
著者名
Yamauchi, Moriyasu
著者名
Watanabe, Akihito
著者名
Omori, Koichi
著者名
Yamazaki, Tomoko
著者名
Monden, Nobuya
著者名
Kudo, Naomi
著者名
Arai, Makoto
著者名
Yonekura, Syuji
著者名
Asakage, Takahiro
著者名
Nekado, Takahiro
著者名
Yamada, Takayuki
e-Rad_Researcher
30312359
著者名
Homma, Akihiro
言語
英語
キーワード
Nivolumab
Long-term survivors
Recurrent or metastatic head and neck cancer
Subsequent chemotherapy
発行日
2021-12-23
出版者
Springer
収録物名
International journal of clinical oncology
巻(号)
27
ページ
95-104
抄録
Background We have previously reported the effectiveness and safety of nivolumab in patients with head and neck cancer (HNC) in real-world clinical practice in Japan. Here, we report long-term outcomes from this study in the overall population and subgroups stratified by subsequent chemotherapy. Methods In this multicenter, retrospective observational study, Japanese patients with recurrent or metastatic (R/M) HNC receiving nivolumab were followed up for 2 years. Effectiveness endpoints included overall survival (OS), OS rate, progression-free survival (PFS), and PFS rate. Safety endpoints included the incidence of immune-related adverse events (irAEs). Results Overall, 256 patients received a median of 6.0 doses (range: 1-52) of nivolumab over a median duration of 72.5 days (range: 1-736). Median OS was 9.5 months [95% confidence interval (CI) 8.2-12.0] and median PFS was 2.1 months (95% CI 1.8-2.7). A significant difference between 2-year survivors (n = 62) and non-2-year survivors was observed by median age (P = 0.0227) and ECOG PS (P = 0.0001). Of 95 patients who received subsequent chemotherapy, 54.7% received paclitaxel +/- cetuximab. The median OS and PFS from the start of paclitaxel +/- cetuximab were 6.9 months (95% CI 5.9-11.9) and 3.5 months (95% CI 2.3-5.5), respectively. IrAEs were reported in 17.2% of patients. Endocrine (7.0%) and lung (4.3%) disorders were the most common irAEs; kidney disorder (n = 1) was newly identified in this follow-up analysis. Conclusions Results demonstrated the long-term effectiveness of nivolumab and potential effectiveness of subsequent chemotherapy in patients with R/M HNC in the real-world setting. Safety was consistent with that over the 1-year follow-up.
資源タイプ
学術雑誌論文
出版タイプ
Version of Record
PISSN
1341-9625
関連情報 (isIdenticalTo)
出版社版DOI
https://doi.org/10.1007/s10147-021-02047-y